Skip to content
DataLookout
Menu

NCT07933692

Edaravone Dexborneol for Blood-Brain Barrier Repair in Acute Anterior Circulation Stroke

StatusRecruiting
PhasePhase 4
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Change in Ktrans (blood-brain barrier permeability) measured by DCE-MRI
Timeframe: From baseline (24-48 hours after stroke onset) to day 9±2 after treatment

Secondary (20)

Change in serum Occludin level
Change in serum Fibronectin level
Change in serum MMP-9 level
Change in serum UCHL1 level
Change in serum NOS level
Show 15 moreShow less
Change in serum NSE level
Change in serum GFAP level
Change in serum EAA level
NIHSS score at day 9±2
mRS score at day 9±2
MMSE score at day 9±2
MoCA score at day 9±2
NIHSS score at day 90±7
mRS score at day 90±7
MMSE score at day 90±7
MoCA score at day 90±7
Hemorrhagic transformation
New cerebrovascular events during the study
Death during the study
Other adverse events during the study

Arms and interventions

Control GroupActive comparator

Participants receive edaravone 30mg BID intravenous drip for 9±2 days, plus standard stroke treatment.

Intervention GroupExperimental

Participants receive edaravone dexborneol 30mg/7.5mg BID intravenous drip for 9±2 days, plus standard stroke treatment.

Drugs: Edaravone, Edaravone Dexborneol

Sites

1 site in 1 country

  • Shandong Provincial Hospital Affiliated to Shandong First Medical UniversityJinan, Shandong, China